The European Commission has approved Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy for treating metastatic non-squamous non-small cell lung cancer (NSCLC).
The approval applies to first-line treatment of adult patients with metastatic NSCLC. For patients with EGFR mutant or ALK-positive NSCLC, the combo therapy is only indicated if appropriate targeted therapies have failed.
The commission’s green light was based on data from Roche’s Phase 3 study, which showed the combo therapy helped patients live significantly longer when compared with just Avastin and chemotherapy, the company said.
The FDA approved the Tecentriq-Avastin combo for treating NSCLC in December 2018. The agency had already cleared Tecentriq for treating metastatic NSCLC patients who have disease progression during or after platinum chemotherapy.